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IntroductIon
G protein-coupled estrogen receptor (GPER), also 
called GPR30, is a newly found estrogen receptor belonging 
to G protein-coupled receptor (GPCR) family [1, 2]. 
GPER is extensively expressed in numerous tissues such as 
breast, uterus, ovary and brain. It has been reported to play 
physiological roles in regulating the functions of cerebral, 
endocrine and reproductive system etc. [3, 4]. Estrogen 
binding with GPER can activate multiple down-stream 
effectors, including the production of cAMP [5], calcium 
mobilization [6, 7], PI3K/Akt and Hippo/YAP/TAZ pathway 
activation [7–9] and EGFR/MAPK transactivation [7, 10]. 
GPER has also been reported to contribute to pathological 
responses such as cancer cells proliferation, migration and 
invasion, especially breast cancer development [3, 10].
Recently, high protein levels of GPER have been 
reported to positively correlate with increased tumor size, 
distant metastasis and poor prognosis of breast cancer 
[11, 12]. In vivo study from transgenic mice tumor model 
showed that deletion of GPER reduced the size of mammary 
tumors and lung metastasis, indicating that GPER is critical 
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AbstrAct
G protein-coupled estrogen receptor (GPER) plays an important role in mediating 
the effects of estradiol. High levels of GPER have been implicated to associate with 
the malignant progress of invasive breast cancer (IBC). However, the mechanisms by 
which GPER protein levels were regulated remain unclear. In this study, PDZ protein 
Na+/H+ exchanger regulatory factor (NHERF1) was found to interact with GPER in 
breast cancer cells. This interaction was mediated by the PDZ2 domain of NHERF1 
and the carboxyl terminal PDZ binding motif of GPER. NHERF1 was demonstrated to 
facilitate GPER expression at post-transcriptional level and improve GPER protein 
stability by inhibiting the receptor degradation via ubiquitin-proteasome pathway 
in a GPER/NHERF1 interaction-dependent manner. In addition, GPER protein levels 
are positively associated with NHERF1 protein levels in a panel of estrogen receptor 
(ER)-positive breast cancer cells. Furthermore, analysis of clinical IBC data from The 
Cancer Genome Atlas (TCGA) showed no significant difference in GPER mRNA levels 
between ER-positive IBC and normal breast tissues. However, gene set enrichment 
analysis (GSEA) showed that GPER signaling is ultra-activated in ER-positive IBC 
when compared with normal and its activation is positively associated with NHERF1 
mRNA levels. Taken together, our findings identify NHERF1 as a new binding partner 
for GPER and its overexpression promotes protein stability and activation of GPER in 
ER-positive IBC. Our data indicate that regulation of GPER stability by NHERF1 may 
contribute to GPER-mediated carcinogenesis in ER-positive IBC.
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in breast tumor growth and distant metastasis [13]. The 
detailed molecular mechanisms that lead to up-regulation 
of GPER protein remain unclear. Total protein levels could 
be regulated both from transcriptional and post-translational 
levels. Hypoxia, epidermal growth factor and Insulin-like 
growth factor-I have been implicated to increase GPER 
expression in transcriptional level [14–16]. Meanwhile, 
GPER protein has been reported to display low stability 
with a high turnover rate [17]. However, the molecular 
mechanisms underlying the regulation of GPER stability 
remain to be further elucidated.
The stability of some GPCRs could be regulated by 
binding with PDZ domain containing proteins. Our previous 
study showed that interaction with postsynaptic density-95 
protein (PSD-95) enhanced Mas protein level by increasing 
its stability [18]. Another PDZ protein, CAL, inhibited 
degradation of metabotropic glutamate receptor 5a and β1-
adrenergic receptor via interaction with the receptors [19, 
20]. GPER is also a member of GPCRs and possesses a 
PDZ-binding motif at its C-terminal. PDZ proteins PSD95 
and synaptic associated protein 97 (SAP97) could bind with 
GPER and regulate the signaling and trafficking of GPER in 
hippocampal dendritic spines or HEK-293 cells respectively 
[21–23]. However, neither GPER/PDZ protein interaction 
in breast cancer cells nor the modulation of GPER stability 
by PDZ proteins has been reported so far. Na+/H+ exchanger 
regulatory factor (NHERF1) is a PDZ protein with well 
reported roles in the regulation of stability of its binding 
partners [24, 25]. NHERF1 is highly expressed in breast 
carcinoma and positively correlated with tumor size and 
grade, especially in estrogen receptor (ER)-positive breast 
carcinoma [26–28]. Our previous study demonstrated that 
NHERF1 can interact with PTEN and enhance PTEN 
protein stability [24]. Interestingly, GPER possesses a PDZ 
binding motif similar to PTEN (S/T-X-V). Thereafter, we 
speculate that NHERF1 may also interact with GPER and 
regulate its expression level.
In this study, we found that NHERF1 interacted 
with GPER via the PDZ2 domain of NHERF1 and 
the C-terminal of GPER. Further, NHERF1 enhanced 
the stability of GPER through inhibition of GPER 
ubiquitination. By analyzing clinical breast cancer data 
from TCGA, we also found a positive correlation between 
NHERF1 expression and GPER pathway activation in 
ER-positive breast cancer. These findings provide a new 
insight into the regulatory mechanism of the GPER protein 
by NHERF1 in breast cancer cells.
results
NHERF1 is identified as a novel GPER-
associated protein 
To test the possibility of GPER and NHERF1 
interaction, we first performed GST pull-down analysis. 
GST-NHERF1 fusion protein was used to pull down the 
lysates of HEK-293 cells stably transfected with Flag-
GPER (HEK-GPER). As shown in Figure 1A, Flag-GPER 
was robustly detected in GST-NHERF1 pull-down fraction, 
whereas no detectable immunoreactivity was observed 
in the GST control pull-down complex (Figure 1A), 
indicating that GPER interacts with NHERF1. 
To verify this interaction in cells, HEK-293 cells 
were transfected with GFP-NHERF1 in the presence or 
absence of Flag-GPER. Immunoprecipitation (IP) of Flag-
GPER was followed by Western blotting and a strong 
NHERF1 signal was found in Flag-GPER-IP complex 
(Figure 1B). These results were further verified by co-IP of 
endogenous NHERF1 with endogenous GPER in MCF-7 
breast cancer cells (Figure 1C). Taken together, these data 
indicate that NHERF1 is a novel binding protein of GPER.
C-terminal of GPER binds to the PDZ2 domain 
of NHERF1 
NHERF1 possesses two non-identical tandem PDZ 
domains and a carboxyl-terminal (CT) ezrin-binding domain 
[29]. To identify the specific domain of NHERF1 responsible 
for this interaction, each domain of NHERF1 was 
subjected to GST pull-down assay separately (Figure 2A). 
Immunoblotting results showed that GPER robustly bound to 
PDZ2, but not PDZ1 or CT domain of NHERF1 (Figure 2B). 
To further determine interaction sites of GPER, the 
valine375 residue of GPER, which is the main determinant 
for its binding to PSD-95 [21], was mutated to alanine 
(GPER-V375A). A further GST pull-down experiment 
was performed using GST-NHERF1. As shown in 
Figure 2C, the point mutation of GPER dramatically 
abolished its binding capacity to NHERF1, revealing the 
requirement of the C-terminal of GPER for the GPER/
NHERF1 interaction. Consistently, results of reverse co-IP 
showed that cellular interaction with NHERF1 also needed 
intact C-terminal of GPER (Figure 2D). Taken together, 
these results suggest that the interaction between GPER and 
NHERF1 is specifically mediated by the NHERF1-PDZ2 
domain and the C-terminal of GPER.
GPER co-localizes with NHERF1 in breast 
cancer cells 
To further confirm GPER/NHERF1 interaction 
in intact cells, MCF-7 cells were double stained using 
anti-GPER and anti-NHERF1 antibodies. Our data 
showed strong co-localization of GPER with NHERF1 
intracellularly by forming multiple spots in cytoplasm, 
especially areas surrounding the nucleus in MCF-7 cells 
(Figure 3A–3D). To examine the specificity of this co-
localization, Flag-GPER-wt or Flag-GPER-V375A were 
transfected into MCF-7 cells respectively. Cells were then 
stained with anti-Flag and anti-NHERF1 antibodies. As 
shown in Figure 3H, a significant fraction of Flag-GPER-wt 
co-localized with NHERF1. In contrast, the co-localization 
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between Flag-GPER and NHERF1 was dramatically 
diminished when their interaction was abrogated by 
mutation of the C-terminal valine to alanine (V375A) 
(Figure 3L). Similar results were also detected in T47D 
breast cancer cells (data not shown). These data, combined 
with the findings from the co-IP (Figures 1B–1C, 2D) and 
GST pull-down (Figure 2C) experiments, indicate that 
GPER interacts with NHERF1 in breast cancer cells and 
this interaction requires intact C-terminal of GPER.
NHERF1 increases the expression level of GPER 
protein at the post-translational level 
We next explored the potential functional 
significance of the GPER/NHERF1 interaction. In the 
immunoprecipitation studies, we noted that the expression 
level of GPER-wt was significantly higher than that of 
the GPER-V375A mutant when the same amount of 
plasmid was co-transfected with GFP-NHERF1. The 
expression of Flag-GPER-wt and Flag-GPER-V375A 
were adjusted to similar levels through transfection with 
different amounts of the respective constructs, which 
would allow comparison of NHERF1 association with 
the wild-type receptor or the mutant one (Figure 2D). 
In further experiments, we found that co-expression 
of NHERF1 could positively regulate total protein 
expression level of GPER-wt, but not GPER-V375A 
(Figure 4A). Thus, it appears that GPER/NHERF1 
interaction complex may be involved in the regulation of 
GPER expression level. To further confirm these results 
in breast cancer cells, NHERF1 was knocked down in 
MCF-7 cells using shNHERF1. As expected, inhibition 
of NHERF1 resulted in a significant down-regulation of 
GPER protein (Figure 4B, lanes 1, 2). Rescue experiment 
in which NHERF1 is re-introduced in MCF-7-shNHERF1 
cells showed that GPER protein levels were recovered 
(Figure 4B, lanes 3, 4). Consistent with what we found 
in MCF-7 cells, similar effects of NHERF1 on GPER 
expression were also found in T47D and SK-BR-3 cells 
after NHERF1 overexpression or knock-down (Figure S1). 
In addition, we further examined the correlation between 
endogenous proteins levels of NHERF1 and GPER in 
a panel of ER-positive breast cancer cell lines (MCF-7, 
T47D, ZR-75-1 and BT474 cells). We found that cells 
expressing higher protein levels of NHERF1 exhibited 
a higher protein level of GPER, suggesting a positive 
correlation between expression of GPER and NHERF1 in 
ER-positive breast cancer cells (Figure 4C).
Figure 1: NHERF1 is identified as a novel GPER-associated protein. (A) GPER interacts with NHERF1 in vitro. Lysates of 
HEK-293 cells that stably transfected with Flag-GPER (HEK-GPER) were incubated with GST or GST-NHERF1, followed by Western 
blotting using anti-Flag antibody. GST and GST-NHERF1 fusion proteins were stained by Coomassie blue dye (lower panel). (b) Cellular 
association of full-length Flag-GPER with GFP-NHERF1 in HEK-293 cells. HEK-293 cells were transfected with GFP-NHERF1 in the 
presence or absence of Flag-GPER. The cells were then lysed and immunoprecipitated using anti-Flag affinity gel. The immunoprecipitate 
samples (IP) and whole cell lysates (Input) were analyzed by Western blotting with anti-Flag or anti-GFP antibodies. (c) GPER associates 
with NHERF1 in MCF-7 cells. The lysates of MCF-7 cells were subjected to immunoprecipitation using anti-GPER antibody. Lysates and 
immunoprecipitated samples were probed with anti-GPER or anti-NHERF1 antibodies to detect the presence of GPER and NHERF1. Blots 
are representative of three to five independent experiments. Input, whole cell lysates; IP, immunoprecipitation.
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We next explored whether NHERF1 increases GPER 
level by regulating GPER mRNA expression. Our results 
showed that although GPER protein levels varied after 
NHERF1 knock-down or overexpression, the GPER mRNA 
levels were unchanged in both cases (Figure 4D–4E). 
These data indicate that regulation of GPER expression by 
NHERF1 is not at mRNA level. NHERF1 may facilitate 
GPER expression at post-translational level. To test this 
hypothesis, we further measured the turnover rates of GPER 
protein after overexpression or knock-down of NHERF1. 
As shown in Figure 5A–5B, NHERF1 overexpression 
significantly reduced the turnover rate of GPER-wt, whereas 
had little effect on GPER-V375A. Consistently, knock-
down of NHERF1 expression robustly enhanced GPER-wt 
degradation (Figure 5C). Taken together, the data indicate 
that NHERF1-mediated up-regulation of GPER protein 
levels is independent of gper transcriptional regulation and 
the GPER/NHERF1 interaction is required for enhanced 
GPER stability by NHERF1.
NHERF1 inhibits the ubiquitin-proteasome 
degradation of GPER 
Intracellular protein degradation occurs through the 
lysosomal and/or the ubiquitin-proteasome degradation 
pathway. To explore which pathway is involved in GPER 
degradation, Western blotting analysis of HEK-GPER cell 
lysates was performed following treatment with either the 
lysosome inhibitor chloroquine or the proteasome inhibitor 
MG132. As shown in Figure 6A, an obvious increase 
in GPER protein level was detected in response to the 
treatment of MG132, but not chloroquine, suggesting that 
degradation of GPER protein occurs via the proteasome 
pathway, which is consistent with previous study [17]. 
To further confirm the involvement of the proteasome 
degradation pathway, HEK-GPER cells were treated with 
MG132 at different time points and doses respectively. As 
shown in Figure 6B–6C, GPER protein levels significantly 
increased in a time and dose dependent manner when the 
proteasome pathway was inhibited (Figure 6B–6C). 
To further verify that the regulation of NHERF1 on 
GPER stability is associated with the ubiquitin-proteasome 
pathway, we assessed the effects of NHERF1 on GPER 
protein ubiquitination in HEK-293 cells. As shown in 
Figure 6D, similar levels of Flag-GPER proteins were 
exhibited in all lanes detected in Western blotting, 
suggesting that NHERF1 has little or no effect on total 
GPER protein levels when ubiquitin-proteasome pathway 
was blocked by MG132. However, a remarkable reduction 
of GPER-wt ubiquitination was detected in cells co-
expressed with NHERF1. In contrast, NHERF1 had little 
effect on the ubiquitination levels of the GPER-V375A, 
Figure 2: Interaction of NHERF1 and GPER is mediated via the C-terminal of GPER and the PDZ2 domain of 
NHERF1. (A) Schematic diagram of GST-NHERF1 fusion proteins used in GST-pull down experiments. (b) GPER interacts specifically 
with the PDZ2 domain of NHERF1. Lysates of HEK-GPER were incubated with GST or GST fusion proteins containing different domains 
of NHERF1. Precipitates were subjected to Western blotting with anti-Flag antibody. Coomassie blue staining showed equal loading of the 
fusion proteins (bottom panels). (c) Association of NHERF1 and GPER via C-terminal of GPER. Equal amounts of purified GST or GST-
NHERF1 fusion protein beads (lower panel) were used to pull down lysates from HEK-293 cells that transfected with Flag-GPER-wt or 
Flag-GPER-V375A respectively. Precipitates were detected by Western blotting using anti-Flag antibody. (d) The point mutation of GPER 
(GPER-V375A) abolishes the interaction between GPER and NHERF1 in cells. HEK-293 cells were either transfected with Flag-GPER-
wt or Flag-GPER-V375A together with or without GFP-NHERF1. Cell lysates were then immunoprecipitated using anti-Flag affinity gel. 
Immunoprecipitated samples were subjected to Western blotting using anti-Flag or anti-GFP antibodies. The expression levels of Flag-
GPER-wt and Flag-GPER-V375A were adjusted to similar levels through transfection with different amounts of the respective constructs. 
The experiments were repeated at least three times. 
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suggesting that GPER ubiquitination is inhibited by the 
interaction with NHERF1. These data were consistent 
with the results from our confocal microscopy experiment. 
When co-localized with NHERF1, GPER-wt displayed 
weak co-localization with proteasome 20S α/β subunits 
(Figure 7D, 7G). In contrast, GPER-V375A showed little 
co-localization with NHERF1 but marked retention in 
the proteasome (Figure 7K, 7N). These findings indicate 
that overexpression of NHERF1 increases GPER protein 
stability by blocking ubiquitin-proteasome degradation of 
GPER.
NHERF1 positively associates with activation 
of GPER downstream signaling in ER-positive 
invasive breast cancer specimens 
Based on the findings that GPER-NHERF1 
interaction enhanced the stability of GPER protein, we 
further defined whether these findings have clinical 
relevance. Considering the findings by other group that 
GPER expression levels were different between ER-
positive and ER-negative breast cancer [12], we first 
examined the gene expression levels of GPER in TCGA 
data set of invasive breast cancer (IBC) specimens. It was 
found that there was no significant difference in GPER 
mRNA levels between ER-positive IBC and normal 
breast tissues, whereas the GPER mRNA levels in ER-
negative IBC was much lower compared with normal 
tissues (Figure 8A). This result indicates that regulation 
of GPER expression in ER-negative IBC occurred at pre-
translational level. We further analyzed the activation 
of GPER by GSEA in normal breast tissue and ER-
positive IBC specimens. As shown in Figure 8B, GPER 
downstream genes were mainly enriched in ER-positive 
IBC subgroup. This finding indicates that GPER signaling 
is ultra-activated in ER-positive IBC when compared with 
normal breast tissues, which is consistent with the high 
levels of GPER protein detected in clinical IBC specimens 
associated with poor prognosis [13, 30]. To detect whether 
NHERF1 was associated with this process, we next 
Figure 3: NHERF1 co-localizes with GPER in MCF-7 cells. (A–d) Endogenous GPER and NHERF1 are co-localized in MCF-
7 cells. MCF-7 cells were stained with anti-GPER (A) and anti-NHERF1 (B) antibodies followed by visualized using Alexa 488- and 
Alexa 594-conjugated secondary antibodies. Co-localization of GPER and NHERF1 is shown in yellow color in merged image (D). 
(e–H) Wild type GPER co-localizes with NHERF1 in MCF-7 cells. MCF-7 cells were transfected with Flag-GPER-wt, and then incubated 
with anti-Flag (E) and anti-NHERF1 (F) primary antibodies followed by staining with Alexa 488- and Alexa 594-conjugated secondary 
antibodies. Nucleuses were stained with DAPI (G). Co-localization of Flag-GPER-wt and NHERF1 is shown in yellow color in panel (H). 
(I–l) Mutation in the C-terminal of GPER abolishes its co-localization with NHERF1 in MCF-7 cells. MCF-7 cells were transfected with 
Flag-GPER-V375A and then stained using anti-Flag (I) and anti-NHERF1 (J) antibodies. Nuclei were detected with DAPI staining (K).
Less co-localization of Flag-GPER-V375A and NHERF1 is detected following merging of the two individual images (L). 
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analyzed the mRNA levels of NHERF1 in normal and IBC 
specimens. It was found that NHERF1 mRNA levels were 
significantly up-regulated in both ER-positive and negative 
IBC, in which the levels of NHERF1 were much higher 
in ER-positive IBC than those in ER-negative specimens 
(Figures 8C, S2). To further investigate the correlation 
between NHERF1 expression and GPER activation in ER-
positive and negative IBC, the specimens were divided 
into high NHERF1 and low NHERF1 groups, and further 
analyzed using GSEA method. As shown in Figure 8D, 
NHERF1 expression was found to positively correlate 
with the activation of GPER signaling in ER-positive 
IBC (Figure 8D). These data indicate that NHERF1 
up-regulation in ER-positive IBC may enhance GPER 
stabilization and activation. In ER-negative IBC, however, 
there was no correlation between NHERF1 expression 
levels with activation of GPER signaling using the same 
gene set (Figure 8E).
Figure 4: NHERF1 enhances the level of the GPER protein at the post-transcriptional level. (A) The protein level of GPER-
wt is increased when NHERF1 is overexpressed. HEK-293 cells were transiently transfected with equal amount constructs of HA-GPER-wt 
or HA-GPER-V375A in the presence or absence of GFP-NHERF1. Protein levels of GPER and NHERF1 were detected by Western blotting 
using anti-HA and anti-GFP antibodies respectively. (b) NHERF1 enhances GPER protein level in breast cancer cells. MCF-7 cells were 
stably transfected with shNC or shNHERF1 (lane 1 and lane 2), and the expression of NHERF1 was rescued by transiently transfected the 
cells with GFP-Vector or GFP-NHERF1 (lane 3 and lane 4). The cell lysates were then tested by Western blotting using anti-GPER, anti-
GFP or anti-NHERF1 antibodies. (c) Correlation of endogenous NHERF1 and GPER protein levels in ER-positive breast cancer cell lines. 
Lysates from four ER-positive breast cancer cell lines were analyzed by Western blotting by using anti-GPER or anti-NHERF1 antibodies. 
(d) Knock-down of NHERF1 expression decreases GPER expression at the post-transcriptional level. HEK-GPER cells were transiently 
transfected with siNHERF1 or scrambled sequence (Scr) respectively. Total RNA of the cells was isolated using Trizol reagent and the 
mRNA levels of GPER, NHERF1, and β-actin were then analyzed by RT-PCR (Left panel). Total cell lysates were subjected to Western 
blotting and detected with anti-Flag, anti-NHERF1, and anti-β-actin antibodies (Right panel). (e) Overexpression of NHERF1 dramatically 
increases GPER expression at post-transcriptional level. HEK-GPER cells were transiently transfected with GFP-NHERF1. The mRNA 
and protein levels of GPER, NHERF1, and β-actin were analyzed by RT-PCR (Left panel) and Western blotting (Right panel) as described 
in panel D, respectively. The experiments were repeated at least three times, with values within each experiment normalized with β-actin 
and analyzed by GraphPad Prism 5. Histogram represents average value of relative GPER protein levels (*p < 0.05). Data were presented 
as means ± SEM.
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dIscussIon
GPER plays an essential role in the rapid responses 
of estrogen and high level of GPER has been reported to 
associate with cancer development, especially in IBC [11]. 
The experiments reported here provide a novel regulatory 
mechanism of GPER stability by interacting with PDZ 
protein NHERF1, which increases GPER protein level by 
inhibiting GPER ubiquitin-proteasome degradation.
GPER has been reported to interact with PDZ 
proteins PSD95 in hippocampal dendritic spines and SAP97 
in HEK-293 cells. In this study, we identified PDZ protein 
NHERF1 as a novel GPER-binding partner in both HEK-
293 and breast cancer cells by using GST pull-down, co-
IP and confocal immunofluorescent assays (Figures 1–3). 
Mutation of Val375 to Ala375 (V375A) in the C-terminal 
of GPER resulted in abolishment of this association 
(Figure 2C–2D, Figure 3I–3L, Figure 7N), suggesting the 
interaction of GPER and NHERF1 is stringent. PSD95 [31, 
32] and SAP97 [33] are mainly expressed in the brain and 
barely expressed in breast epithelium and breast cancer 
cells, whereas NHERF1 is highly expressed in ER-positive 
breast cancer cell lines and specimens [34]. High levels 
of NHERF1 in breast cancer cells suggest its important 
Figure 5: NHERF1 expression improves GPER protein stabilization. (A) Overexpression of NHERF1 reduces the turnover 
rate of Flag-GPER. HEK-GPER cells were transiently transfected GFP-Vector or GFP-NHERF1, then treated with CHX (20 µg/ml) and 
harvested at the indicated time points. The protein levels of GPER, NHERF1, and β-actin were analyzed by Western blotting. (b) NHERF1 
has no effect on the protein stabilization of Flag-GPER-V375A. HEK-GPER-V375A cells were transiently transfected with GFP-Vector 
or GFP-NHERF1, then treated with CHX (20 µg/ml) at indicated time points prior to harvest. The protein levels of GPER, NHERF1, and 
β-actin were analyzed by Western blotting. (c) Knock-down of NHERF1 expression enhances Flag-GPER degradation. HEK-GPER cells 
were transiently transfected with siNHERF1 or scrambled sequence (Scr). Cells were then treated with CHX (20 µg/ml) for indicated time 
points. Western blotting was performed to detect the levels of GPER, NHERF1, and β-actin. The experiments were repeated at least three 
times, with values within each experiment normalized to those of β-actin and analyzed by GraphPad Prism 5. The plot shows relative decay 
rates of GPER after quantified by Log2. Data were presented as means ± SEM.
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roles in breast cancer. Our data identify NHERF1 as a new 
binding partner for GPER and provide a novel mechanism 
by which GPER protein level is regulated in breast cancer 
cells.
As an adaptor protein, NHERF1 possesses two 
tandem PDZ domains which can interact with different 
proteins. It has been reported that most GPCRs interacted 
with the first PDZ domain of NHERF1, such as PTHR, β2-
AR, κOR and P2Y1 [35]. However, our data here show that 
the interaction of NHERF1 and GPER is highly dependent 
on the second PDZ domain of NHERF1 (Figure 2B). 
GPER was reported to interact with some GPCRs, such 
as corticotropin releasing hormone receptor-1, membrane 
progestin receptor-β and serotonin 5HT-1 receptor [21]. It 
is possible that NHERF1 may scaffold GPER with other 
GPCRs via its two PDZ domains and this possibility needs 
to be further investigated.
In the present finding, we observed that GPER protein 
levels were positively correlated with the levels of NHERF1 
in a panel of breast cancer cells (Figure 4C). Overexpression 
of NHERF1 increased but knock-down of NHERF1 
decreased GPER protein levels (Figure 4, Figure S1). 
Furthermore, we found that NHERF1 regulated GPER 
expression at post-translational levels by blocking GPER 
ubiquitin-proteasome degradation in a GPER/NHERF1 
interaction dependent manner (Figure 6, Figure 7). How 
GPER/NHERF1 interaction regulates the ubiquitination 
of GPER remains elusive. Our previous studies reported 
that NHERF1 retarded ubiquitin-mediated proteasome 
degradation of PTEN by inhibiting the association between 
PTEN and NEDD4, an E3 ubiquitin ligase [24]. It is also 
possible that NHERF1 may suppress recruitment of E3 
ubiquitin ligase of GPER. However, the E3 ubiquitin ligase 
of GPER remains unknown and this hypothesis needs to be 
further explored.
High expression of GPER protein was reported to 
correlate with poor prognosis in breast carcinoma [11]. 
Our result showed that the GPER signaling was robustly 
activated in ER-positive breast cancer specimens by 
GSEA from a TCGA data set (Figure 8B). These findings 
suggest that high levels of GPER in breast cancer may 
result in strong GPER activation which in turn promotes 
tumor progression. Meanwhile, we found no significant 
difference of GPER mRNA levels between ER-positive 
Figure 6: NHERF1 retards the ubiquitin–proteasome proteolysis of GPER protein. (A) The GPER protein is degraded 
via the proteasome pathway. HEK-GPER cells were treated with proteasome inhibitor MG132 or lysosome inhibitor chloroquine for 
4 hours. Then the GPER protein levels were detected by Western blotting. (b) The time course of GPER protein expression is elevated 
by MG132. HEK-GPER cells were treated with MG132 (20 µM) at indicated time points. The levels of Flag-GPER were examined by 
Western blotting. (c) GPER protein levels are increased by MG132 in a dose-dependent manner. HEK-GPER cells were treated with 
different doses of MG132 for 4 hours prior to lysis and then GPER protein levels were examined by Western blotting. (d) Overexpression 
of NHERF1 inhibits GPER ubiquitination via GPER/NHERF1 association. HEK-293 cells were co-transfected with Flag-GPER-wt or 
Flag-GPER-V375A in the presence or absence of GFP-NHERF1. The cells were treated with MG132 (20 µM) for 4 hours and then the 
lysates were immunoprecipitated using anti-Flag affinity gel. The ubiquitin levels of Flag-GPER were probed using anti-Ubiquitin antibody 
in the precipitate fraction. The protein levels of total Flag-GPER and GFP-NHERF1 were detected with anti-Flag and anti-GFP antibodies 
(lower panels). 
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IBC samples and normal breast tissues (Figure 8A). Taken 
together, the above findings suggest that mechanisms 
contributed to GPER overexpression in ER-positive IBC 
may mainly occur at post-transcriptional level. In this 
study, we found that NHERF1 enhanced GPER protein 
stability at post-translational level (Figure 4). In addition, 
overexpression of NHERF1 was associated with aggressive 
clinical parameters and poor prognosis in ER-positive IBC 
[34, 36]. Therefore, it is likely that the elevated GPER in 
ER-positive breast cancer specimens might be induced 
by high levels of NHERF1 which further activate GPER 
signaling. This clinical relevance was supported by our 
GSEA results showing that elevated NHERF1 level was 
positively associated with activation of GPER signaling 
in ER-positive IBC (Figure 8D). Our unpublished data 
provide evidences that upon stimulation with GPER 
Figure 7: Association of NHERF1 inhibits GPER localization in the proteasome. (A–G) With association of NHERF1, 
Flag-GPER-wt shows weak localization in proteasome. MCF-7 cells were transfected with Flag-GPER-wt. Following fixation with 
methanol, cells were incubated with mouse anti-Flag IgG1 (A), rabbit anti-proteasome 20 s α/β (B) and mouse anti-NHERF1 IgG2b 
(E) primary antibodies and then visualized using Alexa 488-conjugated anti-mouse IgG1, Alexa 594-conjugated anti-mouse IgG2b and 
Alexa 647-conjugated anti-rabbit IgG secondary antibodies. Nuclei were visualized with DAPI (C, F). No co-localization of proteasome 
and Flag-GPER-wt was detected in merged image (D). Co-localization of NHERF1 with Flag-GPER-wt was shown in panel (G). (H–n) 
Flag-GPER robustly co-localizes with proteasome when the interaction of GPER and NHERF1 is abolished. MCF-7 cells were transfected 
with Flag-GPER-V375A and then stained as described in panel (A–G). A robust co-localization of proteasome and Flag-GPER-V375A was 
shown in merged image (K). A little co-localization of NHERF1 with Flag-GPER-V375A was detected in panel (N).
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Figure 8: NHERF1 expression level positively associates with GPER activation in ER-positive breast cancer. (A) The 
mRNA levels of GPER are similar in ER-positive invasive breast cancer (IBC) and normal samples but significantly lower in ER-negative 
IBC. Clinical mRNA expression data of IBC are downloaded from Sage Synapse. Significance between the 3 groups was determined 
with a two tailed t-test assuming unequal variances. (b) Activation of GPER downstream gene set is found in ER-positive IBC. GSEA 
plot for target genes of GPER (340 genes) in subgroups (Normal and ER-positive IBC) showed that genes downstream of GPER target 
were abundantly activated in ER-positive IBC compared with that of normal tissues. (c) The mRNA levels of NHERF1 are significantly 
up-regulated both in ER-positive and negative IBC. The mRNA levels of NHER1 were compared in the same way as GPER in panel A. 
(d) GPER downstream gene set is positively associated with NHERF1 level in ER-positive IBC. ER-positive IBC samples were divided 
into high and low NHERF1 expression groups. GSEA plot for target genes of GPER showed that GPER was abundantly activated in 
NHERF1-High subgroup compared with that of NHERF1-Low subgroup. (e) GPER downstream gene set is not associated with NHERF1 
level in ER-negative IBC. ER-negative IBC samples were divided into high and low NHERF1 expression groups. GSEA plot for target 
genes of GPER showed that there was no significant enrichment of GPER gene set in neither NHERF1-High nor NHERF1-Low subgroup. 
False discovery rate (FDR) gives the estimated probability that a gene set with a given normalized ES (NES) represents a false-positive 
finding; FDR < 0.05 is a widely accepted cutoff for the identification of biologically significant gene sets.
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agonist (G-1), activation of the downstream effectors of 
GPER signaling such as ERK and AKT was weakened after 
down-regulation of NHERF in breast cancer cells. Thus, 
it is possible that up-regulation of NHERF1 expression 
may enhance the GPER stabilization and activation, which 
further induces ER-positive breast cancer cell proliferation 
and invasion. However, this hypothesis need to be further 
explored. It is interesting to point out that in ER-negative 
breast cancer, GPER protein expression was regulated not 
only at post-translational level by NHERF1 but also at pre-
translational level. This finding indicates that mechanisms 
associated with the roles of NHERF1 in regulation of 
GPER expression may be more complicated when ER 
expression was absent.
As a scaffolding protein, NHERF1 is able to 
recruit membrane receptors/transporters and cytoplasmic 
signaling proteins to assemble functional complexes. 
However, whether NHERF1 acts as a tumor suppressor or 
oncoprotein in breast cancer still remains elusive. NHERF1 
is reported to suppress breast cancer cell viability when it 
scaffolds with tumor suppressors [37], whereas it becomes 
an oncogenic protein when it interacts with oncoproteins 
[38, 39]. Information regarding how NHERF1 coordinates 
the formation of functional complexes to elicit its dual roles 
still remains limited.
In summary, our study identified a novel interaction 
of NHERF1 and GPER mediated by PDZ2 domain 
of NHERF1 with the carboxyl terminal of GPER. 
Association of NHERF1 improved GPER stabilization by 
inhibiting ubiquitin-mediated proteasome degradation of 
the receptor. It was further confirmed in clinical samples 
that NHERF1 expression level positively correlated 
with GPER signaling activation in ER-positive IBC. 
These findings provide a new insight into the regulatory 
mechanisms of GPER protein stability by NHERF1 in 
breast cancer.
MAtERIAls AND MEtHoDs
Cell culture and transfection 
Human embryonic kidney (HEK)-293 cells and 
breast carcinoma MCF-7 cells were grown in Dulbecco’s 
modified eagle media (DMEM) supplemented with 10% 
fetal bovine serum (FBS). Human breast cancer cell lines 
T47D, ZR-75-1 and SK-BR-3 were maintained in RPMI-
1640 with a supplement of 10% fetal bovine serum (FBS). 
BT474 cells were grown in RPMI-1640 supplemented with 
10% FBS and 0.01 mg/ml insulin. All cells were cultured 
at 37°C in a humidified incubator with 5% CO2. All cell 
culture medium and FBS were purchased from Hyclone 
(Logan, Utah). Lipofectamine 2000 Reagent (Invitrogen, 
Carlsbad, CA) was used for cell transfection. HEK-293 
cells that stably express Flag-GPER or Flag-GPER-V375A 
were selected with the growth medium containing 1 mg/mL 
G418 and then maintained in growth medium containing 
500 μg/mL G418 (Calbiochem, San Diego, CA). 
Antibodies 
The monoclonal rabbit anti-GPER (sc-48525-R) 
and anti-ubiquitin (#3933S) antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA) and 
Cell Signaling Technology (Danvers, MA) respectively. 
The monoclonal mouse anti-NHERF1 IgG2b (MA1-
19292) was purchased from Thermo Fisher (Rockford, 
IL), the monoclonal mouse anti-NHERF1 IgG (#611161) 
was purchased from BD (Franklin Lakes, NJ). The 
polyclonal rabbit anti-HA (#561) and anti-proteasome 
20s α/β (ab22673) antibodies were purchased from MBL 
(Nagoya, Japan) and Abcam (Cambridge, UK) respectively. 
Monoclonal mouse anti-Flag (F3165) antibody was 
purchased from Sigma-Aldrich (St Louis, MO).
Preparation of plasmids 
The constructs encoding Flag-GPER (EX-
M0792-M12) were purchased from Gene Copoeia 
(Guangzhou, China). The V375A mutation of Flag-GPER, 
the wild type HA-GPER and HA-GPER-V375A were 
amplified by PCR using indicated primers shown in Table 1 
and then subcloned into pReceiver-M12 and pCMV-
HA vectors respectively. Each plasmid was individually 
confirmed by DNA sequencing. pSuper.puro luciferase 
control (shNC) plasmid and pSuper.puro shNHERF1 
(targeting the sequence CTGACGAGTTCTTCAAGAA) 
constructs were kind gifts from Dr. M. J. Wheelock 
(University of Nebraska Medical Center, Omaha, NE). 
pEGFP-C2 plasmids encoding full-length NHERF1 and 
pGEX plasmids encoding GST fusions of full-length 
NHERF1, NHERF1-PDZ1, NHERF1-PDZ2 and NHERF1-
CT were kindly provided by Randy Hall (Emory University, 
Atlanta, GA). 
Western blotting
Whole cell lysates or immunoprecipitated samples 
were resolved in 10% SDS-PAGE gels and transferred to 
PVDF membrane (Millipore, MA). After being blocked 
with 5% non-fat dried milk for 1 hour at room temperature, 
membranes were incubated in primary antibody overnight 
at 4°C. Horse radish peroxidase (HRP)-conjugated (ZSGB-
BIO, Beijing, China) or infrared fluorescent dyes (IRDye)-
conjugated (LI-COR Biosciences, Lincoln, NE) secondary 
antibodies were used to detect the immunoreactivity by 
enhanced chemiluminescence (ECL) detection reagents 
(Applygen Technologies, Beijing, China) and Odyssey 
infrared imaging system (LI-COR Biosciences, Lincoln, 
NE) respectively.
Gst fusion protein pull-down assay 
GST pull-down assay was performed as previously 
described [18]. Briefly, equal amounts of GST control or 
GST fusion proteins beads were incubated with equal 
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amounts of cell lysates. After incubation at 4°C for 
3 hours, the samples were centrifuged to collect the beads 
and the beads were washed five times with ice-cold Washing 
Buffer (100 mM NaCl, 10 mM Hepes, pH 7.4, 5 mM 
EDTA, 1 mM benzamidine, 3% BSA and 0.1% Tween-20). 
The bound fractions were eluted from the beads using SDS-
PAGE loading buffer (50 mM Tris/HCl, 100 mM DTT, 2% 
SDS, 0.1% Bromophenol Blue and 10% glycerol), boiled 
for 5 minutes, and then analyzed by Western blotting.
Co-immunoprecipitation experiment 
Co-immunoprecipitation was performed as 
described previously [40]. Flag-GPER and endogenous 
GPER were immunoprecipitated using anti-Flag affinity 
gel (Sigma-Aldrich) or anti-GPER antibody pre-bound to 
protein A/G–agarose beads (Santa Cruz Biotechnology) 
respectively. After the incubation at 4°C for 3 hours, 
agarose beads were washed with Washing Buffer for five 
times. Precipitated fractions were eluted using SDS-PAGE 
loading buffer, boiled for 5 minutes, and subjected to 
Western blotting analysis. 
Rt-PCR 
Total RNA of HEK-293 that transfected with 
indicated Flag-GPER (HEK-GPER) was isolated using 
Trizol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instruction. The GPER and NHERF1 mRNA 
levels were determined using an RT-PCR kit (New England 
Biolabs, Beverly, MA) and primers listed in Table 2. 
PCR reaction mixtures were separated in 1% agarose gel 
and visualized under UV light. Relative GPER mRNA 
abundances versus β-actin mRNA were quantified.
Immunofluorescence 
Immunofluorescence was performed as described 
previously [41]. Cells on glass coverslips were rinsed 
with PBS for three times and then fixed with methanol 
for 20 minutes at −20°C. After washed for three times 
with PBS, primary antibodies were diluted in the blocking 
buffer (1% BSA in PBS) respectively and added to the 
coverslips for 1 hour at room temperature. After being 
washed for three times, coverslips were then incubated 
with Alexa 488/594/647-conjugated secondary antibodies 
(Life Technology, 1:100) for 45 minutes. After being 
washed for three times again, nucleuses were stained with 
DAPI. The coverslips were then mounted on glass slide. 
Immunofluorescence images were visualized with a Leica 
TCS SP8 confocal microscopy system (Leica Camera) with 
a 63X oil immersion objective.
Cycloheximide chase assay 
HEK-GPER or HEK-GPER-V375A cells were 
transiently transfected with GFP or GFP-NHERF1, 
scrambled sequence or siNHERF1 (sequences shown in 
Table 3), respectively. Following 24 hours of transfection, 
cells were treated with 20 µg/ml of cycloheximide (CHX) 
for 0, 20, 30, or 40 minutes respectively. The protein levels 
of Flag-GPER were detected using Western blotting.
Ubiquitination assay
HEK-293 cells were transfected with Flag-GPER-wt 
or Flag-GPER-V375A in the absence or presence of GFP-
NHERF1 respectively. After 24 hours, MG132 (Sigma, 
20 µM) was added and treated for 4 hours. Then cell lysates 
were precipitated using anti-Flag affinity gel, followed by 
Western blotting analysis with anti-ubiquitin antibody.
tCGA data analysis and gene set enrichment 
analysis 
Gene expression profile of invasive breast carcinoma 
(unc.edu BRCA IlluminaHiSeq RNASeqV2.geneExp) 
from The Cancer Genome Atlas (TCGA) database (http://
cancergenome.nih.gov/) was downloaded from Sage 
Synapse (www.synapse.org/). 
The association between gene expression and 
biological processes was analyzed using Gene Set 
Enrichment Analysis (GSEA2-2.2.1, http://www.broad.mit.
edu/gsea/) [42]. GSEA calculates a pathway Enrichment 
Score (ES) that estimates whether genes from pre-defined 
gene set of GPER target genes are enriched among the 
highest- (or lowest-) ranked genes or distributed randomly. 
GPER gene set was defined as genes down-regulated with 
table 1: Primers used in plasmid construction
Plasmid amplified/primer sequence 5′- 3′
HA-GPER-wt
Forward primer
Reverse primer 
HA-GPER-V375A
Forward primer
Reverse primer
Flag-GPER-V375A
Forward primer
Reverse primer
GCGAATTCGAATGGATGTGACTTCCC
TGGGTACCCTACACGGCACTGCTG
GCGAATTCGAATGGATGTGACTTCCC
TGGGTACCCTACGCGGCACTGCTG
ATCTCGAGGTCACGCTGGGCTTCATCG 
ATCGCCGGCGCTACGCGGCACTGCTGAAC
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at least 10% reduction in MCF-7 cells treated with siGPER 
(GSE7033, dataset obtained from NIH Gene Expression 
Omnibus). Default settings were used and thresholds for 
significance were determined by permutation analysis (1000 
permutations). False Discovery Rate (FDR) was calculated. 
A gene set is considered significantly enriched when the 
FDR score is < 0.05.
statistical analysis 
Statistical analyses were performed using the 
software GraphPad Prism 5. Results are expressed as 
mean ± SEM. One-way analysis of variance followed by 
Tukey’s multiple comparison test was used to determine 
statistical significances. Statistical significance was 
accepted for p < 0.05.
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